一种能选择性杀死非增殖性结核分枝杆菌的新型抗结核药物。
A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis.
作者信息
Mitchison Denis A
机构信息
Division of Cellular & Molecular Microbiology, St. George's, University of London, Cranmer Terrace, London SW18 0RE, UK.
出版信息
Cell Host Microbe. 2008 Mar 13;3(3):122-4. doi: 10.1016/j.chom.2008.02.013.
PMID:18329610
Abstract
An important report by Bryk et al. in this issue of Cell Host & Microbe describes the properties of a rhodanine prodrug active against nonmultiplying Mycobacterium tuberculosis (Mtb). Considering the tolerance of nonreplicating Mtb to most currently available agents, such a drug could be a major addition to our antituberculosis arsenal and would greatly benefit control of the disease.
摘要
布里克等人在本期《细胞宿主与微生物》上发表的一篇重要报告描述了一种对非增殖型结核分枝杆菌（Mtb）有活性的罗丹宁前药的特性。鉴于非复制型Mtb对目前大多数可用药物具有耐受性，这样一种药物可能会成为我们抗结核药物库中的一项重要补充，并将极大地有助于控制该疾病。
Zotero 插件